People on Ozempic Are Drinking Way Less
Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.
Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests
Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research presented at the European Congress on Obesity (ECO 2025) has found.
Ozempic Has Caused Thousands to Lose Weight Dramatically—Now Their Closets Are for Sale
Novo Nordisk, the maker of Ozempic, just released its first-quarter results, and they’re eye-popping: $4.4 billion in revenue, up 14% from the same period last year. That surge has sent the company’s stock price soaring. But the more interesting story is why. The answer is simple: demand for obesity treatments is up 67%. The Ozempic […]
The truth about GLP-1 medications for weight loss: What every patient should know
For years, weight loss has been sold as a simple math problem: eat less, move more, and the pounds will melt away. But if that were true, we wouldn’t have an obesity epidemic affecting over 40 percent of adults in the U.S. Now, a new class of medications—GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and […]
GLP-1 Medications Overtake Traditional Weight-Loss Drugs
The popularity of glucagon-like peptide-1 (GLP-1) receptor agonists continues, with use of tirzepatide and semaglutide surpassing that of traditional weight-lowering medications.
A natural alternative to Ozempic may have just been discovered
Ozempic has gained fame as a powerful drug for controlling blood sugar and curbing cravings as a weight loss drug. But what if the body had its own built-in version? New research suggests it just might. Scientists have identified a gut microbe that could serve as a natural Ozempic, offering a way to manage diabetes […]
Research Paper – GIPR Antagonism and GLP-1R Agonism Metabolic Effects
Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros JD, Knerr PJ, Finan B, DiMarchi RD, Sloop KW, Samms RJ, Theis FJ, Tschöp MH, Müller TD. GIPR agonism and antagonism decrease body weight […]